Potential bias in pharmacoepidemiological studies due to the length of the drug free period: A study on antidepressant drug use in adults in the Netherlands

Pharmacoepidemiology and Drug Safety

Volumn 15, Issue 5, 2006, Pages 338-343

  Gardarsdottir, Helga ^a   Heerdink, Eibert R ^a   Egberts, Antoine C G ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Antidepressive agent; Bias (epidemiology); Cohort studies; Databases; Depression; Incidence; Methods; Pharmacoepidemiology

Indexed keywords

5 HYDROXYTRYPTOPHAN; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOSULEPIN; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

ADULT; AGE DISTRIBUTION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION; DRUG USE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; BIAS (EPIDEMIOLOGY); COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; TIME FACTORS;

EID: 33744501490     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1223     Document Type: Article

References (35)

1. van Eijk ME, Bahri P, Dekker G, et al. Use of prevalence and incidence measures to describe age-related prescribing of antidepressants with and without anticholinergic effects. J Clin Epidemiol 2000; 53: 645-651.
2. Murphy JM, Laird NM, Monson RR, et al. A 40-year perspective on the prevalence of depression: The Stirling County Study. Arch Gen Psychiatry 2000; 57: 209-215.
3. WHO International Consortium in Psychiatric Epidemiology. Cross-national comparison of the prevalences and correlates of mental disorders. WHO Bulletin 2000; 78: 413-426.
4. Murphy JM, Horton NJ, Laird NM, et al. Anxiety and depression: A 40-year perspective on relationships regarding prevalence, distribution, and comorbidity. Acta Psychiatr Scand 2004; 109: 355-375.
5. Meijer WE, Heerdink ER, Leufkens HG, et al. Incidence and determinants of long-term use of antidepressants. Eur J Clin Pharmacol 2004; 60: 57-61.
6. Ustun TB, Ayuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004; 184: 386-392.
7. Olfson M, Marcus SC, Pincus HA, et al. Antidepressant prescribing practices of outpatient psychiatrists. Arch Gen Psychiatry 1998; 55: 310-316.
8. Hemels ME, Koren G, Einarson TR. Increased use of antidepressants in Canada: 1981-2000. Ann Pharmacother 2002; 36: 1375-1379.
9. Lawrenson RA, Tyrer F, Newson RB, et al. The treatment of depression in UK general practice: Selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Affect Disord 2000; 59: 149-157.
10. Stafford RS, MacDonald EA, Finkelstein SN. National patterns of medication treatment for depression, 1987 to 2001. Prim Care Companion J Clin Psychiatry 2001; 3: 232-235.
11. Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims databases in pharmacoepidemiological research: The accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995; 48: 999-1009.
12. Lau HS, de Boer A, Beuning KS, et al. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997; 50: 619-625.
13. Melfi CA, Croghan TW. Use of claims data for research on treatment and outcomes of depression care. Med Care 1999; 37: AS77-80.
14. Barbui C, Tognoni G, Garattini S. Clinical databases of patients receiving antidepressants. The missing link between research and practice? J Affect Disord 2002; 70: 191-196.
15. Hansen DG, Sondergaard J, Vach W, et al. Antidepressant drug use in general practice: Inter-practice variation and association with practice characteristics. Eur J Clin Pharmacol 2003; 59: 143-149.
16. Henriksson S, Boethius G, Hakansson J, et al. Indications for and outcome of antidepressant medication in a general population: A prescription database and medical record study, in Jamtland county, Sweden, 1995. Acta Psychiatr Scand 2003; 108: 427-431.
17. Movig KL, Leufkens HG, Belitser SV, et al. Selective serotonin reuptake inhibitor-induced urinary incontinence. Pharmacoepidemiol Drug Saf 2002; 11: 271-279.
18. Thiessen BQ, Wallace SM, Blackburn JL, et al. Increased prescribing of antidepressants subsequent to beta-blocker therapy. Arch Intern Med 1990; 150: 2286-2290.
19. Rosholm JU, Gram LF, Isacsson G, et al. Changes in the pattern of antidepressant use upon the introduction of the new antidepressants: A prescription database study. Eur J Clin Pharmacol 1997; 52: 205-209.
20. Egberts AC, Veenstra M, de Jong-van den Berg LT. Antidepressant drug choice for first users in two regions in The Netherlands. Pharm World Sci 1999; 21: 132-136.
21. Rahimtoola H, Buurma H, Tijssen CC, et al. Incidence and determinants of antidepressant drug use in migraine patients. Int Clin Psychopharmacol 2003; 18: 331-339.
22. Isacsson G, Boethius G, Henriksson S, et al. Selective serotonin reuptake inhibitors have broadened the utilisation of antidepressant treatment in accordance with recommendations. Findings from a Swedish prescription database. J Affect Disord 1999; 53: 15-22.
23. Bingefors K, Isacson D, Von Knorring L, et al. Antidepressant-treated patients in ambulatory care long-term use of non-psychotropic and psychotropic drugs. Br J Psychiatry 1996; 168: 292-298.
24. Rosholm JU, Andersen M, Gram LF. Are there differences in the use of selective serotonin reuptake inhibitors and tricyclic antidepressants? A prescription database study. Eur J Clin Pharmacol 2001; 56: 923-929.
25. Hansen DG, Sondergaard J, Vach W, et al. Socio-economic inequalities in first-time use of antidepressants: A population-based study. Eur J Clin Pharmacol 2004; 60: 51-55.
26. Hoencamp E, Haffmans PM, Griens AM, et al. A 3.5-year naturalistic follow-up study of depressed out-patients. J Affect Disord 2001; 66: 267-271.
27. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 1999; 156: 1000-1006.
28. Spijker J, de Graaf R, Bijl RV, et al. Duration of major depressive episodes in the general population: Results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Br J Psychiatry 2002; 181: 208-213.
29. Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry 2000; 157: 229-233.
30. Herings RM, Bakker A, Stricker BH, et al. Pharmaco-morbidity linkage: A feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 1992; 46: 136-140.
31. Mantel-Teeuwisse AK, Klungel OH, Verschuren WM, et al. Comparison of different methods to estimate prevalence of drug use by using pharmacy records. J Clin Epidemiol 2001; 54: 1181-1186.
32. Anonymous. Anatomical Therapeutic Chemical (ATC) Classification Index. WHO Collaborating Centre for Drug Statistics Methodology: Oslo, 2002.
33. Altman DG. Comparing groups-categorical data. In Practical Statistics for Medical Research, Altman DG (ed.). Chapman & Hall: London, 1991; 229-276.
34. Central Bureau of Statistics, The Netherlands. Retrieved 4 August 2004, from www.cbs.nl
35. Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, et al. Long term persistence with statin treatment in daily medical practice. Heart 2004; 90: 1065-1066.